Are all heparins safe for on-pump heart surgery?
- 3 May 2016
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 15 (7) , 897-901
Abstract
Background: Intravenous Panpharma heparin® was used in all on-pump cardiac surgery in our heart-surgery department for a short period. This brand of heparin replaced the previous Choay heparin® heparin supplied by the Sanofi-Aventis Laboratory. Unusual postoperative bleedings over this period prompted us to evaluate postoperative hemostasis by comparing these two heparins. Methods: We compared data from patients who had undergone on-pump cardiac surgery during Panpharma heparin® period (group P, 257 patients) to those how received Choay heparin® (group C, 194 patients). Results: Despite group P receiving a significantly lower dose of heparin (mean dose 21,000 IU/CEC) compared to group C (mean dose 22,000 IU/CEC) (p = 0.05), the number of surgical re-explorations needed to perfect postoperative hemostasis was significantly higher for group P (3.5% vs. 0) (p = 0.01). Heparin anti-Xa activity after surgery was higher in group P at postoperative h1 and h12 compared to group C, which explained reoperations for hemostasis. Conclusion: Despite standardization, variations remain regarding anticoagulant activity between different manufacturing processes and heparin preparations. Surgical teams need to be aware that the biological effects of different brands of heparin may not be as expected and could endanger a usually safe procedure, such as cardiac surgery.Keywords
This publication has 24 references indexed in Scilit:
- Heparin Mapping Using Heparin Lyases and the Generation of a Novel Low Molecular Weight HeparinJournal of Medicinal Chemistry, 2010
- Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008Pharmacoepidemiology and Drug Safety, 2010
- Ethics and observational studies in medical research: various rules in a common frameworkInternational Journal of Epidemiology, 2009
- Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromesExpert Opinion on Drug Safety, 2009
- Lessons learned from the contamination of heparinNatural Product Reports, 2009
- Surgical Reexploration After Cardiac Operations: Why a Worse Outcome?The Annals of Thoracic Surgery, 2008
- Guideline on antiplatelet and anticoagulation management in cardiac surgeryEuropean Journal of Cardio-Thoracic Surgery, 2008
- 1976–1983, a critical period in the history of heparin: the discoveryof the antithrombin binding siteBiochimie, 2003
- Selective appearance of heparin in mammalian tissues during developmentBiochimica et Biophysica Acta (BBA) - General Subjects, 1982
- Heparin: A Mucopolysaccharide and an Active Antithrombotic DrugCirculation, 1959